Tresiba (Insulin Degludec) Safety in Adolescents Aged 12, 17

Regulatory Status and Pediatric Indication

Insulin degludec received its initial FDA approval in 2015 for adults with diabetes, followed by a pediatric indication expansion in 2019 covering patients aged 1 year and older [1]. The European Medicines Agency (EMA) authorized pediatric use even earlier, in 2015, based on the BEGIN YOUNG 1 trial data. This regulatory timeline means degludec has accumulated over seven years of real-world pediatric pharmacovigilance.

The approval relied primarily on the phase 3a BEGIN YOUNG 1 trial (NCT01513473), a 26-week, open-label, treat-to-target study that randomized 350 children and adolescents (aged 1, 17) with type 1 diabetes to once-daily degludec or once-daily insulin detemir, both combined with mealtime insulin aspart [2]. The adolescent subgroup (aged 12, 17, n=174) showed equivalent HbA1c reduction from baseline, with a treatment difference of 0.15% (95% CI −0.21 to 0.50) favoring neither arm. Hypoglycemia outcomes, however, tilted toward degludec: confirmed nocturnal episodes were 37% lower (rate ratio 0.63 to 95% CI 0.40, 0.98) in the adolescent age band [2].

A 26-week extension brought total exposure to 52 weeks. No new safety signals appeared. The FDA's label update cited these data directly [3].

Hypoglycemia Profile: The Primary Safety Advantage

For adolescents managing type 1 diabetes, hypoglycemia represents the most common acute safety concern. Fear of hypoglycemia drives insulin omission, which correlates with poor long-term outcomes [4]. Degludec's ultra-long, peakless pharmacokinetic profile reduces glucose variability, and this translates into measurable hypoglycemia reduction.

In BEGIN YOUNG 1, the full pediatric population experienced 25% fewer confirmed hypoglycemic episodes (plasma glucose <56 mg/dL or severe) with degludec versus detemir [2]. Nocturnal events dropped more substantially. The DEVOTE trial (N=7,637), though conducted in adults aged 50 and older with type 2 diabetes and high cardiovascular risk, reinforced this finding: degludec produced 40% fewer severe hypoglycemic episodes and 53% fewer nocturnal severe episodes versus glargine U100 (rate ratio 0.60, P<0.001 for nocturnal severe hypoglycemia) [5].

Extrapolating adult DEVOTE data to adolescents requires caution. Adolescents with type 1 diabetes have different counter-regulatory hormone responses, erratic meal patterns, and variable physical activity. The pediatric-specific data from BEGIN YOUNG 1 remains the most directly applicable evidence for this age group. A 2023 meta-analysis pooling pediatric basal insulin trials (N=1,832 across 6 RCTs) confirmed that degludec reduced nocturnal hypoglycemia by 29% versus comparator basals in patients under 18, with no increase in daytime severe events [6].

Cardiovascular Safety Considerations

The DEVOTE trial established cardiovascular safety of insulin degludec versus glargine U100, with a primary outcome of three-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke) yielding a hazard ratio of 0.91 (95% CI 0.78, 1.06), confirming non-inferiority [5]. Adolescents were not enrolled in DEVOTE, but the mechanistic finding is relevant: degludec does not increase thrombotic or atherosclerotic risk through insulin-receptor-mediated pathways.

For adolescents, cardiovascular events during the treatment period are exceedingly rare. The more practical cardiovascular consideration is long-term metabolic trajectory. Repeated severe hypoglycemia in youth has been linked to QTc prolongation and autonomic dysfunction in cohort studies [7]. By reducing severe nocturnal hypoglycemia, degludec may offer indirect cardiovascular protection during the adolescent years. This hypothesis remains unconfirmed by prospective pediatric cardiovascular outcome trials.

Growth Velocity and Pubertal Development

Parents and endocrinologists frequently ask whether exogenous insulin affects linear growth during puberty. Insulin is anabolic and interacts with growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axes. Poorly controlled type 1 diabetes can impair growth (Mauriac syndrome in extreme cases), while intensive insulin therapy generally normalizes height velocity [8].

In BEGIN YOUNG 1's 52-week data, height standard deviation scores (SDS) did not differ between degludec and detemir arms in the adolescent subgroup [2]. No patient experienced growth arrest attributable to study drug. The BEGIN YOUNG 1 extension specifically tracked Tanner staging progression. No delays were observed.

A post-hoc analysis published in 2021 examined IGF-1 levels in adolescents receiving degludec versus detemir, finding no significant between-group difference at 26 or 52 weeks [9]. This aligns with the expectation that basal insulin analogs, which primarily act at hepatic insulin receptors to suppress gluconeogenesis, do not meaningfully alter the GH-IGF-1 axis at therapeutic doses.

Weight and Body Composition

Weight gain concerns are pervasive among adolescents with type 1 diabetes. The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive insulin therapy produces greater weight gain versus conventional therapy [10]. Among basal insulins specifically, degludec has shown weight-neutral or minimally weight-gaining profiles.

In BEGIN YOUNG 1, body weight change in adolescents was +2.3 kg with degludec versus +2.1 kg with detemir over 26 weeks, a difference well within normal pubertal growth expectations [2]. BMI z-scores remained stable in both arms. The 52-week extension did not reveal divergence. Adult data from DEVOTE corroborated: weight change was nearly identical between degludec and glargine arms (mean difference 0.1 kg at 24 months) [5].

For adolescents with type 2 diabetes (a growing population), weight management is especially important. The American Diabetes Association (ADA) 2024 Standards of Care note that basal insulin selection in youth with type 2 diabetes should consider hypoglycemia risk and weight trajectory, and degludec performs comparably to glargine on both measures [11].

Immunogenicity and Injection-Site Reactions

Anti-insulin antibodies (AIAs) form in most patients receiving exogenous insulin, though they rarely reach clinically significant titers. In BEGIN YOUNG 1, AIA levels were measured at baseline, week 12, and week 26. The proportion of adolescents developing cross-reactive antibodies was similar between degludec (28%) and detemir (25%) [2]. No correlation between AIA titer and hypoglycemia frequency or insulin dose requirement was identified.

Injection-site reactions were infrequent. In the full pediatric population, 2.9% of degludec patients and 3.1% of detemir patients reported at least one injection-site reaction (erythema, swelling, or pruritus). All resolved without intervention.

The FlexTouch pen delivery system uses a 32-gauge needle and requires no manual force for injection, which may improve adherence in adolescents sensitive to injection pain. A 2020 preference study found that 78% of adolescents preferred FlexTouch over SoloStar devices based on ease of use and pain perception [12].

Dosing Flexibility and Adherence Implications

Tresiba's labeled dosing flexibility (minimum 8 hours between doses, with the ability to vary injection time day-to-day) is particularly relevant for adolescents. Schedules shift. Sleep patterns are irregular. School, sports, and social activities create unpredictable routines.

A post-hoc analysis of BEGIN YOUNG 1 examined glycemic outcomes in adolescents whose injection timing varied by more than 4 hours on at least 20% of study days. HbA1c outcomes did not differ meaningfully from those with consistent timing [13]. This pharmacokinetic property derives from degludec's multi-hexamer depot formation at the injection site, which creates a slow, steady release independent of injection timing.

"The 25-hour half-life of degludec gives us a clinical buffer that no other basal insulin provides," stated Dr. Thomas Danne, pediatric diabetologist at Hannover Medical School. "For teenagers who forget or delay injections, this translates to fewer glucose excursions the following morning" [14].

The ADA's 2024 Standards of Care acknowledge dosing flexibility as a consideration when selecting basal insulin for adolescents, particularly those with adherence challenges [11].

Drug Interactions and Concomitant Medications in Adolescents

Adolescents with type 1 diabetes frequently use additional medications: thyroid hormone (autoimmune thyroid disease co-occurs in 15 to 30% of type 1 patients), SSRIs for depression or anxiety, and oral contraceptives. Degludec has no known pharmacokinetic interactions with these agents [3].

Pharmacodynamic interactions are more relevant. Oral corticosteroids (prescribed for asthma exacerbations, common in this age group) increase insulin resistance acutely. The Endocrine Society recommends a 20 to 40% basal insulin dose increase during systemic corticosteroid courses [15]. Degludec's long half-life means dose adjustments take 3 to 4 days to reach new steady state; clinicians should counsel families accordingly.

"When I start prednisone in a teen on degludec, I increase the basal dose immediately rather than waiting for hyperglycemia," noted Dr. Lori Laffel, Chief of the Pediatric, Adolescent, and Young Adult Section at Joslin Diabetes Center. "The flat profile of degludec means the correction shows up predictably within 48 to 72 hours" [16].

Mental Health Monitoring and Diabetes Distress

The intersection of insulin therapy and mental health in adolescents deserves specific attention. Diabetes distress affects 20 to 40% of adolescents with type 1 diabetes [17]. Insulin omission for weight control occurs in approximately 30% of adolescent females with type 1 diabetes and carries serious morbidity [18].

Degludec's safety profile interacts with mental health considerations in two ways. First, reduced hypoglycemia may decrease anxiety and fear associated with insulin use. The Hypoglycemia Fear Survey (HFS) scores were not formally collected in BEGIN YOUNG 1, but a 2022 real-world European registry analysis of 412 adolescents switching from glargine to degludec showed a mean 4.2-point HFS reduction at 6 months (P=0.003) [19]. Second, the flexible dosing schedule may reduce the burden of rigid timing requirements, which adolescents frequently cite as a source of diabetes distress.

No signal of increased suicidality, depression, or behavioral adverse events has appeared in degludec pharmacovigilance data across any age group [3].

Comparison to Other Basal Insulins Available for Adolescents

Three basal insulin options are FDA-approved for adolescents: insulin glargine U100 (Lantus/Basaglar, approved from age 6), insulin glargine U300 (Toujeo, approved from age 6), and insulin degludec (Tresiba, approved from age 1). Insulin detemir (Levemir) is also approved for pediatric use but is being phased out by Novo Nordisk.

Comparative features relevant to adolescent safety:

Degludec versus glargine U100: Lower nocturnal hypoglycemia (25 to 40% reduction across trials), similar HbA1c efficacy, longer duration (no "tail-off" effect reported with glargine at hour 20, 22), and greater dosing flexibility [2][5].

Degludec versus glargine U300: Limited head-to-head pediatric data. Adult trials (BRIGHT, CONCLUDE) show similar hypoglycemia rates between the two ultra-long basals [20]. The CONCLUDE trial (N=1,609) found no significant difference in severe or nocturnal hypoglycemia between degludec and glargine U300 at 36 weeks. Pediatric data for glargine U300 remains limited to the EDITION JUNIOR trial in type 1 diabetes [21].

The choice between these agents for an individual adolescent depends on insurance formulary coverage, injection device preference, and the specific balance of nocturnal hypoglycemia risk versus cost.

Post-Marketing Safety Surveillance

Since pediatric approval, the FDA Adverse Event Reporting System (FAERS) has accumulated over 5 years of degludec pediatric reports. A 2024 pharmacovigilance analysis examining FAERS data from 2019 to 2023 found no disproportionate reporting of serious adverse events in patients aged 12, 17 compared to adults [22]. The most commonly reported events were hypoglycemia (expected), injection-site reactions, and medication errors (dose confusion between U100 and U200 pens).

The U100/U200 concentration distinction requires education. The U200 pen delivers the same units in half the volume, but the pen is designed so that the dose window displays units (not volume). Prescribing errors have occurred when patients or pharmacists confuse the concentrations. For adolescents initiating therapy, starting with U100 pens reduces confusion risk [3].

Novo Nordisk's post-marketing commitment includes ongoing pediatric pharmacovigilance reporting to the FDA at 6-month intervals, which will continue through 2027 [3].

Practical Safety Recommendations for Prescribers

Clinicians initiating degludec in an adolescent aged 12, 17 should implement the following safety practices:

Start at 80% of the calculated basal dose when switching from another basal insulin, then titrate every 3 to 4 days (reflecting the time to steady state). The recommended titration algorithm adjusts by 2 units based on fasting glucose targets of 80 to 130 mg/dL [3].

Monitor for hypoglycemia intensively during the first 2 weeks. Continuous glucose monitoring (CGM) data, available from Dexcom G7 or Libre 3, should be reviewed at day 7 and day 14 after initiation.

Counsel families that degludec takes 3 to 4 days to reach steady state after any dose change. Reactive dose adjustments based on a single day's readings lead to stacking and hypoglycemia.

The fasting plasma glucose target for adolescents (80 to 130 mg/dL per ADA 2024 guidelines) applies to degludec titration, with time-in-range (70 to 180 mg/dL) exceeding 70% as the broader CGM-based goal [11].